Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nobuaki Mamesaya, MD"'
Autor:
Hiroaki Kanemura, MD, MPH, PhD, Toshihide Yokoyama, MD, Ryu Nakajima, MD, PhD, Atsushi Nakamura, MD, PhD, Hiroaki Kuroda, MD, PhD, Yoshitaka Kitamura, MD, PhD, Hiroyasu Shoda, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihiro Miyata, MD, PhD, Tatsuro Okamoto, MD, PhD, Kyoichi Okishio, MD, PhD, Masahide Oki, MD, PhD, Yuichi Sakairi, MD, PhD, Toyofumi Fengshi Chen-Yoshikawa, MD, PhD, Tadashi Aoki, MD, Tatsuo Ohira, MD, PhD, Isao Matsumoto, MD, PhD, Kiyonobu Ueno, MD, PhD, Takuro Miyazaki, MD, PhD, Haruhisa Matsuguma, MD, PhD, Hideoki Yokouchi, MD, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Isamu Okamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Masayuki Takeda, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100658- (2024)
Introduction: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence
Externí odkaz:
https://doaj.org/article/6165423210284cf69a0cf2aac07b491b
Autor:
Junko Tanizaki, MD, PhD, Hiroaki Kuroda, MD, PhD, Toshihide Yokoyama, MD, Makoto Takahama, MD, PhD, Hiroyasu Shoda, MD, PhD, Atsushi Nakamura, MD, PhD, Yoshitaka Kitamura, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihisa Kadota, MD, PhD, Kenji Sawa, MD, PhD, Kyoichi Okishio, MD, PhD, Morihito Okada, MD, PhD, Chihiro Suminaka, MS, Kenta Noda, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Kenji Chamoto, PhD, Tasuku Honjo, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100590- (2023)
Introduction: Perioperative treatment in NSCLC has gained marked attention with the introduction of immune checkpoint inhibitors. Such a paradigm shift has given us additional opportunities to evaluate potential biomarkers in patients with these cura
Externí odkaz:
https://doaj.org/article/3f386ee3f72d427a96a00d99cb19bacc
Autor:
Kosei Doshita, MD, Yuya Tabuchi, MD, Hirotsugu Kenmotsu, MD, PhD, Shota Omori, MD, Takanori Kawabata, MD, Hiroaki Kodama, MD, Naoya Nishioka, MD, PhD, Eriko Miyawaki, MD, PhD, Yuko Iida, MD, PhD, Nobuaki Mamesaya, MD, Haruki Kobayashi, MD, Ryo Ko, MD, PhD, Kazushige Wakuda, MD, Akira Ono, MD, PhD, Tateaki Naito, MD, PhD, Haruyasu Murakami, MD, PhD, Keita Mori, PhD, Hideyuki Harada, MD, PhD, Takeshi Kaneko, MD, PhD, Toshiaki Takahashi, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 2, Pp 101129- (2023)
Purpose: This study aimed to clarify the characteristics of and evaluate the risk factors for radiation pneumonitis (RP) induced by chemoradiation therapy (CRT) using accelerated hyperfractionated (AHF) radiation therapy (RT) in patients with limited
Externí odkaz:
https://doaj.org/article/ff29a9793bab47478d01d6840d0a25e3
Autor:
Taichi Miyawaki, MD, Tateaki Naito, MD, PhD, Akihro Kodama, MD, Naoya Nishioka, MD, Eriko Miyawaki, MD, Nobuaki Mamesaya, MD, Takahisa Kawamura, MD, PhD, Haruki Kobayashi, MD, Shota Omori, MD, Kazushige Wakuda, MD, Akira Ono, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Haruyasu Murakami, MD, PhD, Akifumi Notsu, PhD, Keita Mori, PhD, Hideyuki Harada, MD, PhD, Masahiro Endo, MD, PhD, Kazuhisa Takahashi, MD, PhD, Toshiaki Takahashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100020- (2020)
Introduction: Programmed cell death 1 (PD-1) inhibitors have become standard treatment for patients with advanced NSCLC. However, few studies have focused on the impact of cancer cachexia on the efficacy of PD-1 or programmed death-ligand 1 (PD-L1) i
Externí odkaz:
https://doaj.org/article/b4419d311f174e4794372d4d06ea913f